Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 4/20 | 0.32 |
| ▸ | NOS1 | P29475 | 4/20 | 0.32 |
| ▸ | NOS2 | P35228 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466147 | 1.00 | ARG1 (0.36) | ARG1CYP1A2NOS3NOS1NOS2 | |
| SCHEMBL466181 | 1.00 | ARG1 (0.36) | ARG1CYP1A2NOS3NOS1NOS2 | |
| SCHEMBL15798281 | 1.00 | ARG1 (0.36) | ARG1CYP1A2NOS3NOS1NOS2 | |
| SCHEMBL14199658 | 0.83 | CYP2D6 (0.32) | ARG1ALDH1A1CYP2D6CTDSP1 | |
| SCHEMBL466084 | 0.83 | CYP2D6 (0.32) | ARG1ALDH1A1CYP2D6CTDSP1 | |
| SCHEMBL466085 | 0.83 | CYP2D6 (0.32) | ARG1ALDH1A1CYP2D6CTDSP1 | |
| SCHEMBL7213243 | 0.83 | CYP2D6 (0.32) | ARG1ALDH1A1CYP2D6CTDSP1 | |
| SCHEMBL466142 | 0.83 | CYP2D6 (0.32) | ARG1ALDH1A1CYP2D6CTDSP1 | |
| Hydrochloric Acid SCHEMBL907394 | 0.82 | CYP2D6 (0.31) | ARG1CYP2D6CTDSP1 | |
| Hydrochloric Acid SCHEMBL907395 | 0.82 | CYP2D6 (0.31) | ARG1CYP2D6CTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| EP-2277850-A1 | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | Merz Pharma GmbH & Co. KGaA (DE) | 2011-01-26 | — | — | EP | claimed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | claimed |
| US-20100298442-A1 | 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-11-25 | — | — | US | claimed |
| EP-1682109-B1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO KGAA (DE) | 2008-10-15 | — | — | EP | claimed |
| US-20070105961-A1 | 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2007-05-10 | — | — | US | claimed |
| EP-1682109-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-07-26 | — | — | EP | claimed |
| WO-2005079779-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-01 | — | — | WO | claimed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | claimed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | claimed |
| EP-1318800-B1 | 1-AMINO-ALKYLCYCLOHEXANES AS TRYPANOCIDAL AGENTS | MERZ PHARMA GMBH & CO KGAA (DE) | 2005-01-26 | — | — | EP | claimed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | claimed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | claimed |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170027885-A1 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2017-02-02 | — | — | US | disclosed |
| WO-2005084655-A1 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF AGITATION AND OTHER BEHAVIORAL DISORDERS, ESPECIALLY THOSE ASSOCIATED WITH ALZHEIMER’S DISEASE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-15 | — | — | WO | disclosed |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | FOREST LABORATORIES, INC. (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2005044228-A2 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-05-19 | — | — | WO | disclosed |
| US-20050014743-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | FOREST LABORATORIES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | ARG1 2351/4885CYP1A2 511/4885NOS3 3210/4885 |
| US-20070105961-A1 | 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | HTR3A, CHRNA3, HTR3B | ARG1 3913/4885CYP1A2 1109/4885NOS3 536/4885 |
| US-20170027885-A1 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS | OTC, CNR2, CNR1 | ARG1 2382/4885CYP1A2 2975/4885NOS3 3149/4885 |
| US-20050113458-A1 | delivering to said cell an 1-aminocyclohexane derivative; for decreasing the level of at least one amyloid peptide produced by a mammalian cell that expresses amyloid precursor protein | APP, BACE1, PSEN1 | ARG1 1754/4885CYP1A2 3220/4885NOS3 3446/4885 |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | ARG1 3618/4885CYP1A2 4284/4885NOS3 3251/4885 |
| US-20050014743-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | GRIN2A, GRIN2B, GRIN3B | ARG1 3568/4885CYP1A2 3450/4885NOS3 1803/4885 |
| US-20100298442-A1 | 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | HTR3A, CHRNA3, HTR3B | ARG1 3665/4885CYP1A2 1043/4885NOS3 442/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | ARG1 3019/4885CYP1A2 608/4885NOS3 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.